---
title: "Janux Therapeutics, Inc. (JANX.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/JANX.US.md"
symbol: "JANX.US"
name: "Janux Therapeutics, Inc."
industry: "生物技術"
---

# Janux Therapeutics, Inc. (JANX.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 美股市場 |
| Website | [www.januxrx.com](https://www.januxrx.com) |

## Company Profile

Janux Therapeutics, Inc.是一家臨床階段的生物制藥公司，開發基于腫瘤激活 T 細胞連接器（TRACTr）和腫瘤激活免疫調節劑（TRACIr）平台技術的免疫療法，以治療癌症患者。其臨床候選藥物包括 JANX007，一種前列腺特異性膜抗原或 PSMA-TRACTr，目前正在進行針對轉移性去勢抵抗性前列腺癌及其他腫瘤血管的成人 1 期臨床試驗；以及 JANX008，一種表皮生長因子受體，目前正在進行針對多種實體癌症的 1 期臨床試驗，包括結直腸癌、頭頸部鱗狀細胞癌、非小細胞肺癌、腎細胞癌、小細胞肺癌、胰腺導管腺癌和三陰性乳腺癌。Janux Therapeutics, Inc.與...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: D (0.66)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 225 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -23.37% |  |
| Net Profit YoY | -68.32% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.83 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 807.18M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 10.00M |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -12.48% | D |
| Profit Margin | -1018.95% | E |
| Gross Margin | -246.29% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -23.37% | E |
| Net Profit YoY | -68.32% | D |
| Total Assets YoY | 47.44% | A |
| Net Assets YoY | 48.84% | A |

#### Cash Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -9.81% | D |
| OCF YoY | -23.37% | E |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.01 | E |

#### Debt Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 4.70% | A |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Janux Therapeutics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-12.48%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-1018.95%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-246.29%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-23.37%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-68.32%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "47.44%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "48.84%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "D",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-9.81%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-23.37%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.01",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "A",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "4.70%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | ADMA生物制藥 (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel制藥 (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -7.92 | 428/604 | - | - | - |
| PB | 0.83 | 69/604 | 1.72 | 1.47 | 0.97 |
| PS (TTM) | 80.72 | 244/604 | 3153.90 | 162.44 | 94.67 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-20T05:00:00.000Z

Total Analysts: **19**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 15 | 79% |
| Overweight | 3 | 16% |
| Hold | 1 | 5% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 13.08 |
| Highest Target | 150.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/JANX.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/JANX.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/JANX.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.